Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?

Area of Science:

• Oncology
• Genetics
• Gynecology

Background:

• Women with BRCA mutations have elevated risks for breast and ovarian cancers.
• Risk-reducing bilateral salpingo-oophorectomy (RRSO) is the primary preventative strategy.
• RRSO often induces premature menopause, impacting quality of life.

Purpose of the Study:

• To review the implications of RRSO in BRCA mutation carriers.
• To discuss the role and safety of hormone replacement therapy (HRT) post-RRSO.
• To highlight the need for comprehensive patient counseling.

Main Methods:

• Literature review on BRCA mutations, RRSO outcomes, and HRT.
• Analysis of existing evidence regarding HRT safety in BRCA carriers.
• Synthesis of current recommendations for managing premature menopause.

Main Results:

• RRSO significantly reduces cancer risk in BRCA carriers.
• Premature menopause following RRSO causes significant symptoms, especially in BRCA1 carriers.
• Short-term HRT is considered safe for BRCA1 carriers and may benefit BRCA2 carriers.

Conclusions:

• BRCA mutation carriers undergoing RRSO require careful management of menopausal symptoms.
• HRT is a viable option for managing post-RRSO menopause, with evidence supporting its safety in BRCA1 carriers.
• Informed counseling is essential to address patient concerns about RRSO outcomes and HRT use.